David Apelian

Biography

 Dr. Apelian has more than 13 years of industry experience from Bristol-Myers Squibb (BMS), Schering Plough and GlobeImmune. He focused on hepatology and infectious disease clinical development. Dr. Apelian was Clinical Director in the Infectious Diseases Group at BMS, serving as medical co-lead for the clinical development and NDA submission of entecavir for chronic hepatitis B viral infection. Prior to BMS, Dr. Apelian served as Clinical Director in the Department of Hepatology/Gastroenterology at Schering Plough, coordinating a supplemental NDA filing for interferon alpha-2b and ribavirin for the treatment of pediatric patients with chronic hepatitis C viral infection. Most recently, Dr. Apelian served as Senior Vice President of Research and Development and Chief Medical Officer at GlobeImmune, where he was responsible for clinical development, regulatory affairs, clinical immunology, development of companion diagnostics, as well as target discovery and preclinical research. Dr. Apelian completed his residency training in Pediatrics at New York Hospital, Cornell Medical Center. He received his MD from the University of Medicine and Dentistry of New Jersey, and his PhD in Biochemistry and BA from Rutgers University. He also holds an MBA from Quinnipiac University.

Research Interest

  clinical development, regulatory affairs, clinical immunology, development of companion diagnostics